X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. REDDYS LAB - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. REDDYS LAB DISHMAN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 27.3 92.0% View Chart
P/BV x 3.3 2.8 119.2% View Chart
Dividend Yield % 0.7 1.0 65.9%  

Financials

 DISHMAN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
DISHMAN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3744,383 8.5%   
Low Rs1292,750 4.7%   
Sales per share (Unadj.) Rs197.8920.1 21.5%  
Earnings per share (Unadj.) Rs21.2126.1 16.8%  
Cash flow per share (Unadj.) Rs34.7183.0 19.0%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.6 141.7%  
Book value per share (Unadj.) Rs179.9685.8 26.2%  
Shares outstanding (eoy) m80.69170.61 47.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.9 32.8%   
Avg P/E ratio x11.928.3 42.0%  
P/CF ratio (eoy) x7.219.5 37.2%  
Price / Book Value ratio x1.45.2 26.9%  
Dividend payout %9.415.9 59.5%   
Avg Mkt Cap Rs m20,306608,481 3.3%   
No. of employees `0000.821.7 3.8%   
Total wages/salary Rs m5,35531,874 16.8%   
Avg. sales/employee Rs Th19,252.77,244.4 265.8%   
Avg. wages/employee Rs Th6,459.51,470.9 439.1%   
Avg. net profit/employee Rs Th2,064.1992.8 207.9%   
INCOME DATA
Net Sales Rs m15,961156,978 10.2%  
Other income Rs m2652,693 9.9%   
Total revenues Rs m16,226159,671 10.2%   
Gross profit Rs m4,10334,587 11.9%  
Depreciation Rs m1,0919,705 11.2%   
Interest Rs m944824 114.6%   
Profit before tax Rs m2,33426,751 8.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6245,237 11.9%   
Profit after tax Rs m1,71121,514 8.0%  
Gross profit margin %25.722.0 116.7%  
Effective tax rate %26.719.6 136.5%   
Net profit margin %10.713.7 78.2%  
BALANCE SHEET DATA
Current assets Rs m11,018118,201 9.3%   
Current liabilities Rs m9,51768,368 13.9%   
Net working cap to sales %9.431.7 29.6%  
Current ratio x1.21.7 67.0%  
Inventory Days Days11060 184.2%  
Debtors Days Days3597 36.0%  
Net fixed assets Rs m16,30472,265 22.6%   
Share capital Rs m161853 18.9%   
"Free" reserves Rs m12,907111,548 11.6%   
Net worth Rs m14,516117,009 12.4%   
Long term debt Rs m4,18910,690 39.2%   
Total assets Rs m29,805200,104 14.9%  
Interest coverage x3.533.5 10.4%   
Debt to equity ratio x0.30.1 315.9%  
Sales to assets ratio x0.50.8 68.3%   
Return on assets %8.911.2 79.8%  
Return on equity %11.818.4 64.1%  
Return on capital %17.521.6 81.2%  
Exports to sales %24.846.3 53.6%   
Imports to sales %3.79.0 41.7%   
Exports (fob) Rs m3,95672,618 5.4%   
Imports (cif) Rs m59614,050 4.2%   
Fx inflow Rs m4,95275,405 6.6%   
Fx outflow Rs m69727,115 2.6%   
Net fx Rs m4,25548,290 8.8%   
CASH FLOW
From Operations Rs m2,78640,476 6.9%  
From Investments Rs m-1,529-19,421 7.9%  
From Financial Activity Rs m-941-17,009 5.5%  
Net Cashflow Rs m3164,046 7.8%  

Share Holding

Indian Promoters % 61.4 25.5 240.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.4 68.5%  
FIIs % 12.7 35.3 36.0%  
ADR/GDR % 0.0 18.5 -  
Free float % 22.1 15.3 144.4%  
Shareholders   46,261 75,885 61.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS